Global
antidiabetics market is expected to reach USD 84.13 billion by 2020. Growing
prevalence of diabetes is the primary driver of this market. Growth in
prevalence of disease causing lifestyle disorders such as irregular dietary
habits and obesity is also expected to boost product demand by triggering
incidence rates of target diseases.
Future
commercialization of products currently in the pipeline and the presence of
large untapped opportunities in the emerging Asia Pacific and Latin American
markets is expected to fuel future market growth.
Insulin
was the most revenue generating segment and its market was valued at over USD
20.0 billion in 2013. Insulin is also one of the most lucrative segments of
this market. Introduction of new products exhibiting higher efficacy coupled
with the presence of favorable government initiatives are some factors
attributing to its market attractiveness.
Read Complete Report with TOC @
http://www.radiantinsights.com/research/antidiabetics-market-analysis-by-product-insulin-biguanides-thiazolodinediones-glp-agonists-sulphonylureas-dpp-4-inhibitors-sglt-2-alpha-glucosidase-inhibitors-meglitinides-and-segment-forecasts-to-2020
Further
key findings from the study suggest:
Long
acting insulin was the leading product segment in 2013 and is expected to grow
at the CAGR of over 15.0% during the forecast period. The introduction of
advanced products, high prices associated with these products and the phasing
out of human insulin are some key factors attributing for its large share.
Rapid
uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina and Onglyza
on account of their once daily dosage regimens and safety profiles catalyzed
the growth of this market.
North
America was the most matured antidiabetics market in 2013 accounting for over
43.0% of the market High market penetration of insulin and other antidiabetics
and the presence of sophisticated reimbursement framework are expected to drive
regional market growth.
Asia
Pacific is expected to present manufacturers with lucrative future growth
opportunities. Large presence of unmet patient needs and rapidly improving
healthcare infrastructure are some factors expected to drive market growth in
the region. The market is also expected to be driven by the introduction of
cheaper products made available by local manufacturers.
Some
key market players of antidiabetics include Sanofi Aventis, Takeda
Pharmaceuticals, Eli Lilly, Oramed Pharmaceuticals Inc., Merck & Co. Inc.,
Novo Nordisk, Bristol-Myers Squibb, Halozyme Therapeutics and Pfizer.
The
market is oligopolistic in nature with few players accounting for over 70% of
the market. Extensive R&D investments aimed at new product development and
entering new markets via government contracts are the key sustainability
strategies adopted by these organizations.
About Us
Radiant Insights is a platform for companies looking to meet their
market research and business intelligence requirements. We assist and
facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For more information visit: Radiant
Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
No comments:
Post a Comment